title: Oral Colostrum Macrophage-activating Factor for Serious Infection and Chronic Fatigue Syndrome: Three Case Reports.
abstract: BACKGROUND
  Gc protein-derived macrophage-activating factor (GcMAF) immunotherapy has been steadily advancing over the last two decades. Oral colostrum macrophage-activating factor (MAF) produced from bovine colostrum has shown high macrophage phagocytic activity. GcMAF-based immunotherapy has a wide application for use in treating many diseases via macrophage activation or for use as supportive therapy.
  
  
  RESULTS
  Three case studies demonstrate that oral colostrum MAF can be used for serious infection and chronic fatigue syndrome (CFS) without adverse effects.
  
  
  CONCLUSIONS
  We demonstrate that colostrum MAF shows promising clinical results in patients with infectious diseases and for symptoms of fatigue, which is common in many chronic diseases.
authors.affiliation: Department of Life System, Institute of Technology and Science, Graduate School, Tokushima University, Tokushima, Japan Saisei Mirai Cell Processing Center, Osaka, Japan Inui Immunotherapy Clinic, Osaka, Japan contact@saisei-mirai.or.jp.
authors.forename: Toshio
authors.initials: T
authors.lastname: Inui
authors.affiliation: Saisei Mirai Cell Processing Center, Osaka, Japan.
authors.forename: Kentaro
authors.initials: K
authors.lastname: Kubo
authors.affiliation: Department of Life System, Institute of Technology and Science, Graduate School, Tokushima University, Tokushima, Japan Saisei Mirai Cell Processing Center, Osaka, Japan.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Kuchiike
authors.affiliation: Department of Life System, Institute of Technology and Science, Graduate School, Tokushima University, Tokushima, Japan.
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Uto
authors.affiliation: Frontiers of Innovative Research in Science and Technology (FIRST), Konan University, Kobe, Japan.
authors.forename: Takahito
authors.initials: T
authors.lastname: Nishikata
authors.affiliation: Division of Food and Drug Evaluation Science, Department of Community Medicine and Social Healthcare Science, Graduate School of Medicine, Kobe University, Kobe, Japan.
authors.forename: Norihiro
authors.initials: N
authors.lastname: Sakamoto
authors.affiliation: Inui Immunotherapy Clinic, Osaka, Japan contact@saisei-mirai.or.jp.
authors.forename: Martin
authors.initials: M
authors.lastname: Mette
mesh_terms: D000368:Aged; D002388:Catastrophic Illness / Q000628:therapy; D003126:Colostrum / Q000276:immunology*; D015673:Fatigue Syndrome, Chronic / Q000209:etiology / Q000628:therapy*; D005260:Female; D005334:Fever / Q000188:drug therapy; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007239:Infections / Q000209:etiology / Q000628:therapy*; D008262:Macrophage Activation / Q000187:drug effects; D016215:Macrophage-Activating Factors / Q000627:therapeutic use*; D008264:Macrophages / Q000187:drug effects / Q000276:immunology; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*; D011247:Pregnancy; D014809:Vitamin D-Binding Protein / Q000627:therapeutic use*
chemical_list: D016215:Macrophage-Activating Factors; D014809:Vitamin D-Binding Protein; C101908:vitamin D-binding protein-macrophage activating factor
keywords: Immunotherapy; cancer; chronic fatigue syndrome (CFS); colostrum; macrophage-activating factor (MAF); myalgic encephalomyelitis (ME)